Prostate Cancer - Results from #60

Diet Quality, Dietary Inflammatory Potential, and Risk of Prostate Cancer Grade Reclassification. October 20, 2024

Molecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review. October 18, 2024

Targeted Prostate Health Checks, a novel system to identify men with prostate cancer-A pilot study. October 18, 2024

Revisiting HER2 in Prostate Cancer from an Inclusive Perspective: From Biomarkers to Omics. October 18, 2024

Sleep and health improvement programme (SHIP) for patients with prostate cancer and caregivers. October 18, 2024

Prostate-specific Membrane Antigen Positron Emission Tomography Before Reaching the Phoenix Criteria for Biochemical Recurrence of Prostate Cancer After Radiotherapy: Earlier Detection of Recurrences. October 18, 2024

Aerobic Physical Activity and Depression Among Patients With Cancer A Systematic Review and Meta-Analysis October 17, 2024

Investigating the pattern of prostate specific antigen screening among E-cigarette smokers within the behavioral risk factor surveillance system. October 17, 2024

General Obesity and Prostate Cancer in Relation to Abdominal Obesity and Ethnic Groups: A US Population-Based Cross-Sectional Study. October 17, 2024

Accuracy of the LaserSAFE technique for detecting positive surgical margins during robot-assisted radical prostatectomy: blind assessment and inter-rater agreement analysis. October 17, 2024

External Validation of a Previously Developed Deep Learning-based Prostate Lesion Detection Algorithm on Paired External and In-House Biparametric MRI Scans. October 17, 2024

Machine learning and explainable artificial intelligence to predict pathologic stage in men with localized prostate cancer. October 17, 2024

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer. October 17, 2024

Copper-67 SAR-bisPSMA Updates October 16, 2024

Association between smoking and prostate cancer survivors' long-term quality of life and function: an analysis of the CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation) study. October 16, 2024

Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval. October 16, 2024

Identification of a 5-gene signature panel for the prediction of prostate cancer progression. October 16, 2024

Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies. October 16, 2024

Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial. October 16, 2024

Positive Guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III Trial in Patients with Recurrence of Prostate Cancer October 15, 2024

Page 4 of 1435